Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06376240
NA

The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes

Sponsor: Maastricht University Medical Center

View on ClinicalTrials.gov

Summary

Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions. Methylglyoxal is a by-product of glycolysis and forms advanced glycation endproducts (AGEs) on proteins and DNA, thereby disrupting their function. Preventing methylglyoxal accumulation and AGEs formation may offer a therapeutic option for treating microvascular complications in diabetics. Pyridoxamine is a vitamin B6 vitamer that scavenges methylglyoxal and thereby inhibits the formation of AGEs. In this study, the researchers investigate whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation.

Official title: The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes: a Double-blind Randomized Placebo-controlled Crossover Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-03-21

Completion Date

2026-12-31

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Pyridoxamine 300mg per day

oral supplement

OTHER

Placebo 300mg placebo per day

oral supplement

Locations (1)

Academic Hospital Maastricht

Maastricht, Netherlands